Badri currently serves as Medical Affairs Lead for the ASPIRE unit at Actelion Pharmaceuticals, which was acquired by Janssen/Johnson & Johnson in 2017. Badri serves as study physician for the largest observational study in the MF variant of cutaneous T-cell lymphoma (PROVe), co-leads the investigator-initiated study program for ASPIRE, and oversees an interdisciplinary effort across medical affairs, field medical, and clinical operations. He has over 15 years of healthcare industry experience including roles in healthcare modeling and analytics, medical affairs, product development strategy & new product planning, regulatory affairs, market research, and business development. He was previously a Senior Medical Director at Archimedes (healthcare modeling and simulation), Director of Business Development and Market Research at Nodality (personalized/predictive medicine), biotechnology equities analyst at Lehman Brothers, Regulatory Team Leader at Genentech, and consultant with McKinsey and Company. Badri earned an A.B. in Biology and Public Policy from Harvard University and an M.D. from Yale University.